Page 3 - Michael Brigham News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ImmuCell has had a backlog of orders for its flagship product, First Defense. “Good problem to have,” says the company’s CEO.

ImmuCell Corporation (NASDAQ:NASDAQ:ICCC) Q1 2022 Earnings Conference Call May 13, 2022 09:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO...

The company has been investing in the gradual expansion of its manufacturing capacity for cattle health products, and the investments are starting to pay off, according to President and CEO Michael Brigham.

How can the admirable and needed concern about addressing climate change in the future be more important than the lives of people in Ukraine today? We should invest in expanded domestic oil production right now and figure out how to reduce that demand over time, while purchasing no oil from Russia. How can our sanctions […]

Date Time Dana-Farber research leads to better understanding of immune system in kidney cancer Two research papers highlight single-cell dissection of kidney tumors to identify new immunotherapy treatments and targets In the last two decades, immunotherapy has emerged as a leading treatment for advanced renal carcinoma cancer (more commonly known as kidney cancer). This therapy is now part of the standard of care, but it doesn’t work for all patients, and almost all patients, no matter how they respond initially, become more resistant to treatment over time. The immune system plays a critic...